The new regulation makes it possible during a pandemic to introduce into the list of essential drugs for the treatment of a new coronavirus infection on an accelerated basis. This was announced by the head of the Ministry of Health of Russia Mikhail Murashko during a visit to the National Medical Research Center for Transplantology and Artificial Organs named after V.I. Academician V.I.Shumakov.
“In the next week, the decision of the commission will be … They are already included in the methodological recommendations,” – leads TASS words by Mikhail Murashko.
Also the minister reportedthat the Federal Antimonopoly Service (FAS), together with the Ministry of Health, will regulate prices for some drugs used to treat a new coronavirus infection.
It was FAS earlier did a request for the reasonableness of the price of the company “Promomed” – the manufacturer of “Areplivira” (faripiravir), the cost of one package of which in retail starts at 12 320 rubles.
Since June this year, it has been included in the recommendations of the Ministry of Health for the treatment, diagnosis and prevention of a new coronavirus infection.
Favipiravir is also produced under the brands Avifavir (ChemRara and RDIF) and Coronavir (R-Pharm). Registration of drugs before the completion of all clinical trials provides for their use only when there is a threat of the spread of emergency situations or the spread of dangerous diseases and in a hospital setting.